Frank Mottola reports a stock award at SUPN

By AlphaYouPublished Nov 2, 2026Form 4

Stocks in this disclosure

Reported activity

Mottola Frank

Reporting filer

Frank Mottola reports a stock award, not an open-market purchase or sale, in Supernus Pharmaceuticals, Inc.. Form 4 filed Nov 2, 2026 lists 1 entry.

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Restricted Stock Unit (derivative)	Mottola Frank	2026-10-30	A	Grant or award	100000	0	100,000	3 days	Filed terms security Title: Restricted Stock Unit conversion Or Exercise Price: 0 transaction Date: 2026-10-30 transaction Form Type: 4 transaction Code: A equity Swap Involved: 0 transaction Shares: 100000 transaction Price Per Share: 0 transaction Acquired Disposed Code: A id: F1 id: F1 underlying Security Title: Common Stock underlying Security Shares: 100000 shares Owned Following Transaction: 100000 direct Or Indirect Ownership: D

Owner: Mottola Frank
Date: 2026-10-30
Code: A
Action: Grant or award
Quantity: 100000
Price: 0
Following holdings: 100,000
Reporting delay: 3 days
Filed terms and references: Filed terms
security Title: Restricted Stock Unit
conversion Or Exercise Price: 0
transaction Date: 2026-10-30
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Shares: 100000
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
id: F1
id: F1
underlying Security Title: Common Stock
underlying Security Shares: 100000
shares Owned Following Transaction: 100000
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Mottola Frank: SVP, Chief Tech. Ops. Officer.
F1: These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.

Prepared automatically from public filing data. Report a correction.